Clinical Trial Designs for Cytostatic Agents and Agents Directed at Novel Molecular Targets

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/B978-012088561-9/50016-8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Design issues of randomized phase II trials and a proposal for phase II screening trials.

  2005cited by this paper
• Dose escalation trial designs based on a molecularly targeted endpoint

  2005cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents.

  2004cited by this paper
• Influence of unrecognized molecular heterogeneity on randomized clinical trials.

  2002cited by this paper
• Clinical trial designs for cytostatic agents: are new approaches needed?

  2001cited by this paper
• Development of Target-Based Antineoplastic Agents

  2000cited by this paper
• Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.

  2000cited by this paper
• Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

  1999cited by this paper
• Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

  1998cited by this paper
• There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.

  1998cited by this paper
• Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998.

  1998cited by this paper
• Accelerated titration designs for phase I clinical trials in oncology.

  1997cited by this paper
• Improved designs for dose escalation studies using pharmacokinetic measurements.

  1996cited by this paper
• Some practical improvements in the continual reassessment method for phase I studies.

  1995cited by this paper
• Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision.

  1993cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• Sample size tables for bounding small proportions.

  1986cited by this paper
• Randomized phase II clinical trials.

  1985cited by this paper

• Host-dependent variables: The missing link to personalized medicine.

  2018cites this paper
• Design and Analysis of Clinical Trials for Predictive Medicine

  2015cites this paper
• Diseños adaptativos para ensayos clínicos fase II o III en pacientes con cáncer en Cuba

  2009cites this paper
• Biometric Research Branch Annual Report 2005

  2006cites this paper
• Clinical trial designs for therapeutic cancer vaccines.

  2005cites this paper